EC Approves Revolution's RASONQUE For Pancreatic Ductal Adenocarcinoma In All EU Member States
The European Commission approved Revolution Medicines' (RVMD) RASONQUE for pancreatic cancer treatment. The drug, previously approved by the FDA, showed improved survival rates in trials. RVMD shares closed at $166.87, down 3.15%.
How this was made

The 30-second read
Why it matters
This is a regulatory approval step that expands the drug’s eligible geography across all EU member states plus Iceland, Norway, and Liechtenstein, following EMA CHMP’s positive opinion and expedited review under the EMA Cancer Medicines Pathfinder project.
Market read
Regulatory approval in Europe is a concrete commercialization catalyst for RVMD, likely improving sentiment and reducing regulatory uncertainty for RASONQUE’s PDAC franchise.
What to watch
The article does not quantify expected EU sales, launch timeline, or reimbursement status, so the market may still discount the financial magnitude until commercialization details emerge.
Background
RASONQUE (daraxonrasib) is an oral, non-covalent, multi-selective RAS inhibitor targeting RAS mutations in pancreatic ductal adenocarcinoma; it received FDA approval on Aug 26, 2026 and now has EC marketing authorization.
Ticker impact
European Commission marketing authorization for RASONQUE (daraxonrasib) expands PDAC availability across the EU/EEA, a direct regulatory milestone for Revolution Medicines.
Likely upward bias as the market prices in broader ex-US launch prospects and reduced probability of further regulatory delays.
The article reports a new EC marketing authorization following a positive EMA CHMP opinion and notes the drug was already FDA-approved in August 2026, making this a meaningful incremental expansion of addressable markets.
Market effects
Supports sentiment for targeted oncology RAS-pathway therapeutics and may lift peer-group expectations for RAS-driven PDAC programs.
Improves near-term access prospects for EU/EEA PDAC patients, potentially accelerating uptake dynamics for RASONQUE versus non-approved alternatives.
Reinforces global regulatory momentum after FDA approval, strengthening the narrative for multinational adoption of RAS-targeted PDAC therapy.
Counterpoint
EC approval does not guarantee rapid uptake; pricing, reimbursement, and competitive sequencing in PDAC could limit near-term revenue impact.
Key entities
- companyRevolution Medicines Inc.
Developer and marketer of RASONQUE (daraxonrasib), now granted EC marketing authorization for PDAC across the EU/EEA.
- drugRASONQUE (daraxonrasib)
RAS-targeted oral inhibitor for pancreatic ductal adenocarcinoma with improved PFS and OS reported from Phase 3 RASolute 302.
- regulatorEuropean Commission (EC)
Granted marketing authorization for RASONQUE across EU member states.
- regulatorEMA CHMP
Issued the positive opinion that preceded EC approval.


